nodes	percent_of_prediction	percent_of_DWPC	metapath
Dorzolamide—CA6—saliva-secreting gland—thyroid cancer	0.0136	0.123	CbGeAlD
Dorzolamide—CA7—trachea—thyroid cancer	0.0108	0.0982	CbGeAlD
Dorzolamide—CA6—head—thyroid cancer	0.00734	0.0668	CbGeAlD
Dorzolamide—CA4—neck—thyroid cancer	0.00721	0.0657	CbGeAlD
Dorzolamide—CA12—trachea—thyroid cancer	0.00701	0.0638	CbGeAlD
Dorzolamide—CA2—neck—thyroid cancer	0.00598	0.0544	CbGeAlD
Dorzolamide—CA4—saliva-secreting gland—thyroid cancer	0.00563	0.0512	CbGeAlD
Dorzolamide—CA5B—thyroid gland—thyroid cancer	0.00497	0.0453	CbGeAlD
Dorzolamide—CA12—head—thyroid cancer	0.00492	0.0448	CbGeAlD
Dorzolamide—CA2—saliva-secreting gland—thyroid cancer	0.00467	0.0425	CbGeAlD
Dorzolamide—CA9—Regulation of gene expression by Hypoxia-inducible Factor—EPO—thyroid cancer	0.00464	0.117	CbGpPWpGaD
Dorzolamide—Psoriasis—Doxorubicin—thyroid cancer	0.00456	0.00537	CcSEcCtD
Dorzolamide—Dry mouth—Vandetanib—thyroid cancer	0.00453	0.00532	CcSEcCtD
Dorzolamide—Oedema—Vandetanib—thyroid cancer	0.00444	0.00522	CcSEcCtD
Dorzolamide—Epistaxis—Sorafenib—thyroid cancer	0.00443	0.0052	CcSEcCtD
Dorzolamide—Keratitis—Doxorubicin—thyroid cancer	0.00442	0.0052	CcSEcCtD
Dorzolamide—CA5B—head—thyroid cancer	0.00441	0.0402	CbGeAlD
Dorzolamide—Hepatomegaly—Epirubicin—thyroid cancer	0.00438	0.00515	CcSEcCtD
Dorzolamide—CA4—trachea—thyroid cancer	0.00434	0.0395	CbGeAlD
Dorzolamide—Redness—Doxorubicin—thyroid cancer	0.00425	0.005	CcSEcCtD
Dorzolamide—Scotoma—Epirubicin—thyroid cancer	0.00408	0.0048	CcSEcCtD
Dorzolamide—Hepatomegaly—Doxorubicin—thyroid cancer	0.00405	0.00476	CcSEcCtD
Dorzolamide—Rash erythematous—Epirubicin—thyroid cancer	0.00405	0.00476	CcSEcCtD
Dorzolamide—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00404	0.00475	CcSEcCtD
Dorzolamide—Insomnia—Vandetanib—thyroid cancer	0.00401	0.00472	CcSEcCtD
Dorzolamide—Paraesthesia—Vandetanib—thyroid cancer	0.00398	0.00468	CcSEcCtD
Dorzolamide—Erythema multiforme—Sorafenib—thyroid cancer	0.00398	0.00468	CcSEcCtD
Dorzolamide—Dyspnoea—Vandetanib—thyroid cancer	0.00395	0.00465	CcSEcCtD
Dorzolamide—Tinnitus—Sorafenib—thyroid cancer	0.00393	0.00462	CcSEcCtD
Dorzolamide—Dyspepsia—Vandetanib—thyroid cancer	0.0039	0.00459	CcSEcCtD
Dorzolamide—CA1—head—thyroid cancer	0.0039	0.0355	CbGeAlD
Dorzolamide—Decreased appetite—Vandetanib—thyroid cancer	0.00386	0.00453	CcSEcCtD
Dorzolamide—Stinging—Epirubicin—thyroid cancer	0.00383	0.0045	CcSEcCtD
Dorzolamide—Fatigue—Vandetanib—thyroid cancer	0.00382	0.0045	CcSEcCtD
Dorzolamide—Pain—Vandetanib—thyroid cancer	0.00379	0.00446	CcSEcCtD
Dorzolamide—Scotoma—Doxorubicin—thyroid cancer	0.00378	0.00444	CcSEcCtD
Dorzolamide—Arrhythmia—Sorafenib—thyroid cancer	0.00376	0.00442	CcSEcCtD
Dorzolamide—Rash erythematous—Doxorubicin—thyroid cancer	0.00374	0.0044	CcSEcCtD
Dorzolamide—Alopecia—Sorafenib—thyroid cancer	0.00372	0.00438	CcSEcCtD
Dorzolamide—Erythema—Sorafenib—thyroid cancer	0.00367	0.00431	CcSEcCtD
Dorzolamide—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00363	0.00427	CcSEcCtD
Dorzolamide—CA2—trachea—thyroid cancer	0.0036	0.0328	CbGeAlD
Dorzolamide—Dysgeusia—Sorafenib—thyroid cancer	0.00359	0.00422	CcSEcCtD
Dorzolamide—Stinging—Doxorubicin—thyroid cancer	0.00354	0.00416	CcSEcCtD
Dorzolamide—Vasodilation—Epirubicin—thyroid cancer	0.00353	0.00415	CcSEcCtD
Dorzolamide—Vasodilation procedure—Epirubicin—thyroid cancer	0.00353	0.00415	CcSEcCtD
Dorzolamide—Abdominal pain—Vandetanib—thyroid cancer	0.00351	0.00412	CcSEcCtD
Dorzolamide—Body temperature increased—Vandetanib—thyroid cancer	0.00351	0.00412	CcSEcCtD
Dorzolamide—CA4—thyroid gland—thyroid cancer	0.00343	0.0313	CbGeAlD
Dorzolamide—Lacrimation increased—Epirubicin—thyroid cancer	0.00336	0.00396	CcSEcCtD
Dorzolamide—Angioedema—Sorafenib—thyroid cancer	0.00335	0.00394	CcSEcCtD
Dorzolamide—Syncope—Sorafenib—thyroid cancer	0.00329	0.00387	CcSEcCtD
Dorzolamide—Vasodilation procedure—Doxorubicin—thyroid cancer	0.00326	0.00384	CcSEcCtD
Dorzolamide—Vasodilation—Doxorubicin—thyroid cancer	0.00326	0.00384	CcSEcCtD
Dorzolamide—Loss of consciousness—Sorafenib—thyroid cancer	0.00322	0.00379	CcSEcCtD
Dorzolamide—Cough—Sorafenib—thyroid cancer	0.0032	0.00376	CcSEcCtD
Dorzolamide—Atrioventricular block—Epirubicin—thyroid cancer	0.0032	0.00376	CcSEcCtD
Dorzolamide—Asthenia—Vandetanib—thyroid cancer	0.00318	0.00374	CcSEcCtD
Dorzolamide—Hypertension—Sorafenib—thyroid cancer	0.00317	0.00372	CcSEcCtD
Dorzolamide—Pruritus—Vandetanib—thyroid cancer	0.00314	0.00369	CcSEcCtD
Dorzolamide—Arthralgia—Sorafenib—thyroid cancer	0.00312	0.00367	CcSEcCtD
Dorzolamide—Lacrimation increased—Doxorubicin—thyroid cancer	0.00311	0.00366	CcSEcCtD
Dorzolamide—CA5B—lymph node—thyroid cancer	0.00309	0.0281	CbGeAlD
Dorzolamide—Dermatitis contact—Epirubicin—thyroid cancer	0.00306	0.0036	CcSEcCtD
Dorzolamide—Abnormal dreams—Epirubicin—thyroid cancer	0.00306	0.0036	CcSEcCtD
Dorzolamide—Dry mouth—Sorafenib—thyroid cancer	0.00305	0.00359	CcSEcCtD
Dorzolamide—CA4—head—thyroid cancer	0.00305	0.0277	CbGeAlD
Dorzolamide—Diarrhoea—Vandetanib—thyroid cancer	0.00303	0.00357	CcSEcCtD
Dorzolamide—Anaphylactic shock—Sorafenib—thyroid cancer	0.00299	0.00352	CcSEcCtD
Dorzolamide—Atrioventricular block—Doxorubicin—thyroid cancer	0.00296	0.00348	CcSEcCtD
Dorzolamide—Shock—Sorafenib—thyroid cancer	0.00294	0.00346	CcSEcCtD
Dorzolamide—Dizziness—Vandetanib—thyroid cancer	0.00293	0.00345	CcSEcCtD
Dorzolamide—Blood urea increased—Epirubicin—thyroid cancer	0.00293	0.00344	CcSEcCtD
Dorzolamide—Dry eye—Epirubicin—thyroid cancer	0.00286	0.00337	CcSEcCtD
Dorzolamide—Anorexia—Sorafenib—thyroid cancer	0.00285	0.00335	CcSEcCtD
Dorzolamide—CA2—thyroid gland—thyroid cancer	0.00285	0.0259	CbGeAlD
Dorzolamide—Dermatitis contact—Doxorubicin—thyroid cancer	0.00283	0.00333	CcSEcCtD
Dorzolamide—Abnormal dreams—Doxorubicin—thyroid cancer	0.00283	0.00333	CcSEcCtD
Dorzolamide—Vomiting—Vandetanib—thyroid cancer	0.00282	0.00332	CcSEcCtD
Dorzolamide—Rash—Vandetanib—thyroid cancer	0.0028	0.00329	CcSEcCtD
Dorzolamide—Dermatitis—Vandetanib—thyroid cancer	0.00279	0.00329	CcSEcCtD
Dorzolamide—Headache—Vandetanib—thyroid cancer	0.00278	0.00327	CcSEcCtD
Dorzolamide—CA9—Regulation of gene expression by Hypoxia-inducible Factor—HIF1A—thyroid cancer	0.00276	0.0694	CbGpPWpGaD
Dorzolamide—Pulmonary oedema—Epirubicin—thyroid cancer	0.00276	0.00324	CcSEcCtD
Dorzolamide—CA1—lymph node—thyroid cancer	0.00273	0.0248	CbGeAlD
Dorzolamide—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00273	0.00321	CcSEcCtD
Dorzolamide—Blood urea increased—Doxorubicin—thyroid cancer	0.00271	0.00318	CcSEcCtD
Dorzolamide—Dyspnoea—Sorafenib—thyroid cancer	0.00267	0.00314	CcSEcCtD
Dorzolamide—Dry eye—Doxorubicin—thyroid cancer	0.00265	0.00311	CcSEcCtD
Dorzolamide—Nausea—Vandetanib—thyroid cancer	0.00263	0.0031	CcSEcCtD
Dorzolamide—Dyspepsia—Sorafenib—thyroid cancer	0.00263	0.0031	CcSEcCtD
Dorzolamide—Decreased appetite—Sorafenib—thyroid cancer	0.0026	0.00306	CcSEcCtD
Dorzolamide—Fatigue—Sorafenib—thyroid cancer	0.00258	0.00303	CcSEcCtD
Dorzolamide—Pain—Sorafenib—thyroid cancer	0.00256	0.00301	CcSEcCtD
Dorzolamide—Pulmonary oedema—Doxorubicin—thyroid cancer	0.00255	0.003	CcSEcCtD
Dorzolamide—CA2—head—thyroid cancer	0.00253	0.023	CbGeAlD
Dorzolamide—Eye pain—Epirubicin—thyroid cancer	0.00249	0.00293	CcSEcCtD
Dorzolamide—Cardiac failure congestive—Epirubicin—thyroid cancer	0.00248	0.00292	CcSEcCtD
Dorzolamide—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00245	0.00288	CcSEcCtD
Dorzolamide—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.00238	0.0028	CcSEcCtD
Dorzolamide—Urticaria—Sorafenib—thyroid cancer	0.00238	0.0028	CcSEcCtD
Dorzolamide—Body temperature increased—Sorafenib—thyroid cancer	0.00237	0.00278	CcSEcCtD
Dorzolamide—Abdominal pain—Sorafenib—thyroid cancer	0.00237	0.00278	CcSEcCtD
Dorzolamide—Eye pain—Doxorubicin—thyroid cancer	0.00231	0.00271	CcSEcCtD
Dorzolamide—Hypoglycaemia—Epirubicin—thyroid cancer	0.00231	0.00271	CcSEcCtD
Dorzolamide—Cardiac failure—Epirubicin—thyroid cancer	0.00231	0.00271	CcSEcCtD
Dorzolamide—Cerebrovascular accident—Epirubicin—thyroid cancer	0.0023	0.0027	CcSEcCtD
Dorzolamide—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.0023	0.0027	CcSEcCtD
Dorzolamide—Pain in extremity—Epirubicin—thyroid cancer	0.00225	0.00265	CcSEcCtD
Dorzolamide—Diplopia—Epirubicin—thyroid cancer	0.00225	0.00265	CcSEcCtD
Dorzolamide—Affect lability—Epirubicin—thyroid cancer	0.00221	0.0026	CcSEcCtD
Dorzolamide—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.00221	0.00259	CcSEcCtD
Dorzolamide—Hypersensitivity—Sorafenib—thyroid cancer	0.0022	0.00259	CcSEcCtD
Dorzolamide—Asthenia—Sorafenib—thyroid cancer	0.00215	0.00252	CcSEcCtD
Dorzolamide—Cardiac arrest—Epirubicin—thyroid cancer	0.00214	0.00252	CcSEcCtD
Dorzolamide—Hypoglycaemia—Doxorubicin—thyroid cancer	0.00213	0.00251	CcSEcCtD
Dorzolamide—Cardiac failure—Doxorubicin—thyroid cancer	0.00213	0.00251	CcSEcCtD
Dorzolamide—CA4—lymph node—thyroid cancer	0.00213	0.0194	CbGeAlD
Dorzolamide—Mood swings—Epirubicin—thyroid cancer	0.00213	0.00251	CcSEcCtD
Dorzolamide—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.00212	0.0025	CcSEcCtD
Dorzolamide—Pruritus—Sorafenib—thyroid cancer	0.00212	0.00249	CcSEcCtD
Dorzolamide—Pain in extremity—Doxorubicin—thyroid cancer	0.00208	0.00245	CcSEcCtD
Dorzolamide—Diplopia—Doxorubicin—thyroid cancer	0.00208	0.00245	CcSEcCtD
Dorzolamide—Affect lability—Doxorubicin—thyroid cancer	0.00205	0.00241	CcSEcCtD
Dorzolamide—Diarrhoea—Sorafenib—thyroid cancer	0.00205	0.00241	CcSEcCtD
Dorzolamide—CA9—Cellular response to hypoxia—EPO—thyroid cancer	0.00205	0.0515	CbGpPWpGaD
Dorzolamide—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.00203	0.00238	CcSEcCtD
Dorzolamide—Cardiac arrest—Doxorubicin—thyroid cancer	0.00198	0.00233	CcSEcCtD
Dorzolamide—Dizziness—Sorafenib—thyroid cancer	0.00198	0.00233	CcSEcCtD
Dorzolamide—Mood swings—Doxorubicin—thyroid cancer	0.00197	0.00232	CcSEcCtD
Dorzolamide—Influenza—Epirubicin—thyroid cancer	0.00194	0.00229	CcSEcCtD
Dorzolamide—Vomiting—Sorafenib—thyroid cancer	0.0019	0.00224	CcSEcCtD
Dorzolamide—Angina pectoris—Epirubicin—thyroid cancer	0.00189	0.00223	CcSEcCtD
Dorzolamide—Rash—Sorafenib—thyroid cancer	0.00189	0.00222	CcSEcCtD
Dorzolamide—Dermatitis—Sorafenib—thyroid cancer	0.00188	0.00222	CcSEcCtD
Dorzolamide—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.00187	0.0022	CcSEcCtD
Dorzolamide—Headache—Sorafenib—thyroid cancer	0.00187	0.0022	CcSEcCtD
Dorzolamide—Bronchitis—Epirubicin—thyroid cancer	0.00187	0.0022	CcSEcCtD
Dorzolamide—Dysuria—Epirubicin—thyroid cancer	0.00182	0.00214	CcSEcCtD
Dorzolamide—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.00181	0.00213	CcSEcCtD
Dorzolamide—Influenza—Doxorubicin—thyroid cancer	0.0018	0.00212	CcSEcCtD
Dorzolamide—Nausea—Sorafenib—thyroid cancer	0.00178	0.00209	CcSEcCtD
Dorzolamide—CA2—lymph node—thyroid cancer	0.00177	0.0161	CbGeAlD
Dorzolamide—Weight decreased—Epirubicin—thyroid cancer	0.00176	0.00207	CcSEcCtD
Dorzolamide—Hyperglycaemia—Epirubicin—thyroid cancer	0.00175	0.00206	CcSEcCtD
Dorzolamide—Angina pectoris—Doxorubicin—thyroid cancer	0.00175	0.00206	CcSEcCtD
Dorzolamide—Bronchitis—Doxorubicin—thyroid cancer	0.00173	0.00203	CcSEcCtD
Dorzolamide—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00172	0.00202	CcSEcCtD
Dorzolamide—Conjunctivitis—Epirubicin—thyroid cancer	0.00169	0.00198	CcSEcCtD
Dorzolamide—Urinary tract infection—Epirubicin—thyroid cancer	0.00169	0.00198	CcSEcCtD
Dorzolamide—Dysuria—Doxorubicin—thyroid cancer	0.00168	0.00198	CcSEcCtD
Dorzolamide—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.00167	0.00197	CcSEcCtD
Dorzolamide—Sweating—Epirubicin—thyroid cancer	0.00166	0.00195	CcSEcCtD
Dorzolamide—Epistaxis—Epirubicin—thyroid cancer	0.00164	0.00192	CcSEcCtD
Dorzolamide—Weight decreased—Doxorubicin—thyroid cancer	0.00163	0.00191	CcSEcCtD
Dorzolamide—Sinusitis—Epirubicin—thyroid cancer	0.00163	0.00191	CcSEcCtD
Dorzolamide—Hyperglycaemia—Doxorubicin—thyroid cancer	0.00162	0.00191	CcSEcCtD
Dorzolamide—Agranulocytosis—Epirubicin—thyroid cancer	0.00162	0.0019	CcSEcCtD
Dorzolamide—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.00159	0.00187	CcSEcCtD
Dorzolamide—Bradycardia—Epirubicin—thyroid cancer	0.00158	0.00186	CcSEcCtD
Dorzolamide—Conjunctivitis—Doxorubicin—thyroid cancer	0.00156	0.00183	CcSEcCtD
Dorzolamide—Urinary tract infection—Doxorubicin—thyroid cancer	0.00156	0.00183	CcSEcCtD
Dorzolamide—Pharyngitis—Epirubicin—thyroid cancer	0.00154	0.00182	CcSEcCtD
Dorzolamide—Sweating—Doxorubicin—thyroid cancer	0.00154	0.00181	CcSEcCtD
Dorzolamide—Epistaxis—Doxorubicin—thyroid cancer	0.00151	0.00178	CcSEcCtD
Dorzolamide—Sinusitis—Doxorubicin—thyroid cancer	0.00151	0.00177	CcSEcCtD
Dorzolamide—Visual impairment—Epirubicin—thyroid cancer	0.0015	0.00176	CcSEcCtD
Dorzolamide—Agranulocytosis—Doxorubicin—thyroid cancer	0.0015	0.00176	CcSEcCtD
Dorzolamide—Erythema multiforme—Epirubicin—thyroid cancer	0.00147	0.00173	CcSEcCtD
Dorzolamide—Bradycardia—Doxorubicin—thyroid cancer	0.00147	0.00172	CcSEcCtD
Dorzolamide—Tinnitus—Epirubicin—thyroid cancer	0.00145	0.00171	CcSEcCtD
Dorzolamide—Pharyngitis—Doxorubicin—thyroid cancer	0.00143	0.00168	CcSEcCtD
Dorzolamide—Arrhythmia—Epirubicin—thyroid cancer	0.00139	0.00164	CcSEcCtD
Dorzolamide—Visual impairment—Doxorubicin—thyroid cancer	0.00139	0.00163	CcSEcCtD
Dorzolamide—Alopecia—Epirubicin—thyroid cancer	0.00138	0.00162	CcSEcCtD
Dorzolamide—Erythema multiforme—Doxorubicin—thyroid cancer	0.00136	0.0016	CcSEcCtD
Dorzolamide—Erythema—Epirubicin—thyroid cancer	0.00135	0.00159	CcSEcCtD
Dorzolamide—Tinnitus—Doxorubicin—thyroid cancer	0.00134	0.00158	CcSEcCtD
Dorzolamide—Tension—Epirubicin—thyroid cancer	0.00133	0.00156	CcSEcCtD
Dorzolamide—Dysgeusia—Epirubicin—thyroid cancer	0.00133	0.00156	CcSEcCtD
Dorzolamide—Nervousness—Epirubicin—thyroid cancer	0.00132	0.00155	CcSEcCtD
Dorzolamide—Back pain—Epirubicin—thyroid cancer	0.00131	0.00154	CcSEcCtD
Dorzolamide—Arrhythmia—Doxorubicin—thyroid cancer	0.00129	0.00151	CcSEcCtD
Dorzolamide—Vision blurred—Epirubicin—thyroid cancer	0.00128	0.0015	CcSEcCtD
Dorzolamide—Alopecia—Doxorubicin—thyroid cancer	0.00127	0.0015	CcSEcCtD
Dorzolamide—Erythema—Doxorubicin—thyroid cancer	0.00125	0.00147	CcSEcCtD
Dorzolamide—Tension—Doxorubicin—thyroid cancer	0.00123	0.00145	CcSEcCtD
Dorzolamide—Dysgeusia—Doxorubicin—thyroid cancer	0.00123	0.00144	CcSEcCtD
Dorzolamide—CA9—Cellular response to hypoxia—HIF1A—thyroid cancer	0.00122	0.0307	CbGpPWpGaD
Dorzolamide—Nervousness—Doxorubicin—thyroid cancer	0.00122	0.00143	CcSEcCtD
Dorzolamide—Vertigo—Epirubicin—thyroid cancer	0.00122	0.00143	CcSEcCtD
Dorzolamide—Syncope—Epirubicin—thyroid cancer	0.00122	0.00143	CcSEcCtD
Dorzolamide—Back pain—Doxorubicin—thyroid cancer	0.00121	0.00143	CcSEcCtD
Dorzolamide—CA9—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.0012	0.0302	CbGpPWpGaD
Dorzolamide—Palpitations—Epirubicin—thyroid cancer	0.0012	0.00141	CcSEcCtD
Dorzolamide—Loss of consciousness—Epirubicin—thyroid cancer	0.00119	0.0014	CcSEcCtD
Dorzolamide—Cough—Epirubicin—thyroid cancer	0.00118	0.00139	CcSEcCtD
Dorzolamide—Vision blurred—Doxorubicin—thyroid cancer	0.00118	0.00139	CcSEcCtD
Dorzolamide—Hypertension—Epirubicin—thyroid cancer	0.00117	0.00138	CcSEcCtD
Dorzolamide—Arthralgia—Epirubicin—thyroid cancer	0.00115	0.00136	CcSEcCtD
Dorzolamide—Chest pain—Epirubicin—thyroid cancer	0.00115	0.00136	CcSEcCtD
Dorzolamide—Anxiety—Epirubicin—thyroid cancer	0.00115	0.00135	CcSEcCtD
Dorzolamide—Discomfort—Epirubicin—thyroid cancer	0.00114	0.00134	CcSEcCtD
Dorzolamide—Dry mouth—Epirubicin—thyroid cancer	0.00113	0.00133	CcSEcCtD
Dorzolamide—Vertigo—Doxorubicin—thyroid cancer	0.00113	0.00132	CcSEcCtD
Dorzolamide—Syncope—Doxorubicin—thyroid cancer	0.00112	0.00132	CcSEcCtD
Dorzolamide—Confusional state—Epirubicin—thyroid cancer	0.00111	0.00131	CcSEcCtD
Dorzolamide—Palpitations—Doxorubicin—thyroid cancer	0.00111	0.0013	CcSEcCtD
Dorzolamide—Anaphylactic shock—Epirubicin—thyroid cancer	0.00111	0.0013	CcSEcCtD
Dorzolamide—Oedema—Epirubicin—thyroid cancer	0.00111	0.0013	CcSEcCtD
Dorzolamide—Loss of consciousness—Doxorubicin—thyroid cancer	0.0011	0.0013	CcSEcCtD
Dorzolamide—Cough—Doxorubicin—thyroid cancer	0.00109	0.00129	CcSEcCtD
Dorzolamide—Shock—Epirubicin—thyroid cancer	0.00109	0.00128	CcSEcCtD
Dorzolamide—Hypertension—Doxorubicin—thyroid cancer	0.00108	0.00127	CcSEcCtD
Dorzolamide—Hyperhidrosis—Epirubicin—thyroid cancer	0.00107	0.00126	CcSEcCtD
Dorzolamide—Arthralgia—Doxorubicin—thyroid cancer	0.00107	0.00126	CcSEcCtD
Dorzolamide—Chest pain—Doxorubicin—thyroid cancer	0.00107	0.00126	CcSEcCtD
Dorzolamide—Anxiety—Doxorubicin—thyroid cancer	0.00106	0.00125	CcSEcCtD
Dorzolamide—Discomfort—Doxorubicin—thyroid cancer	0.00105	0.00124	CcSEcCtD
Dorzolamide—Anorexia—Epirubicin—thyroid cancer	0.00105	0.00124	CcSEcCtD
Dorzolamide—Dry mouth—Doxorubicin—thyroid cancer	0.00104	0.00123	CcSEcCtD
Dorzolamide—Hypotension—Epirubicin—thyroid cancer	0.00103	0.00122	CcSEcCtD
Dorzolamide—Confusional state—Doxorubicin—thyroid cancer	0.00103	0.00121	CcSEcCtD
Dorzolamide—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00102	0.0012	CcSEcCtD
Dorzolamide—Oedema—Doxorubicin—thyroid cancer	0.00102	0.0012	CcSEcCtD
Dorzolamide—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00101	0.00118	CcSEcCtD
Dorzolamide—Shock—Doxorubicin—thyroid cancer	0.00101	0.00118	CcSEcCtD
Dorzolamide—Insomnia—Epirubicin—thyroid cancer	0.001	0.00118	CcSEcCtD
Dorzolamide—Paraesthesia—Epirubicin—thyroid cancer	0.000993	0.00117	CcSEcCtD
Dorzolamide—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000989	0.00116	CcSEcCtD
Dorzolamide—Dyspnoea—Epirubicin—thyroid cancer	0.000986	0.00116	CcSEcCtD
Dorzolamide—Somnolence—Epirubicin—thyroid cancer	0.000983	0.00116	CcSEcCtD
Dorzolamide—Anorexia—Doxorubicin—thyroid cancer	0.000975	0.00115	CcSEcCtD
Dorzolamide—Dyspepsia—Epirubicin—thyroid cancer	0.000973	0.00114	CcSEcCtD
Dorzolamide—Decreased appetite—Epirubicin—thyroid cancer	0.000961	0.00113	CcSEcCtD
Dorzolamide—Hypotension—Doxorubicin—thyroid cancer	0.000956	0.00112	CcSEcCtD
Dorzolamide—Fatigue—Epirubicin—thyroid cancer	0.000953	0.00112	CcSEcCtD
Dorzolamide—Pain—Epirubicin—thyroid cancer	0.000946	0.00111	CcSEcCtD
Dorzolamide—CA9—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.000942	0.0237	CbGpPWpGaD
Dorzolamide—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000932	0.0011	CcSEcCtD
Dorzolamide—Insomnia—Doxorubicin—thyroid cancer	0.000925	0.00109	CcSEcCtD
Dorzolamide—Paraesthesia—Doxorubicin—thyroid cancer	0.000919	0.00108	CcSEcCtD
Dorzolamide—Dyspnoea—Doxorubicin—thyroid cancer	0.000912	0.00107	CcSEcCtD
Dorzolamide—Feeling abnormal—Epirubicin—thyroid cancer	0.000911	0.00107	CcSEcCtD
Dorzolamide—Somnolence—Doxorubicin—thyroid cancer	0.00091	0.00107	CcSEcCtD
Dorzolamide—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000904	0.00106	CcSEcCtD
Dorzolamide—Dyspepsia—Doxorubicin—thyroid cancer	0.000901	0.00106	CcSEcCtD
Dorzolamide—Decreased appetite—Doxorubicin—thyroid cancer	0.000889	0.00105	CcSEcCtD
Dorzolamide—Fatigue—Doxorubicin—thyroid cancer	0.000882	0.00104	CcSEcCtD
Dorzolamide—Urticaria—Epirubicin—thyroid cancer	0.000878	0.00103	CcSEcCtD
Dorzolamide—Pain—Doxorubicin—thyroid cancer	0.000875	0.00103	CcSEcCtD
Dorzolamide—Body temperature increased—Epirubicin—thyroid cancer	0.000874	0.00103	CcSEcCtD
Dorzolamide—Abdominal pain—Epirubicin—thyroid cancer	0.000874	0.00103	CcSEcCtD
Dorzolamide—Feeling abnormal—Doxorubicin—thyroid cancer	0.000843	0.000992	CcSEcCtD
Dorzolamide—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000837	0.000984	CcSEcCtD
Dorzolamide—Hypersensitivity—Epirubicin—thyroid cancer	0.000815	0.000958	CcSEcCtD
Dorzolamide—Urticaria—Doxorubicin—thyroid cancer	0.000813	0.000956	CcSEcCtD
Dorzolamide—Abdominal pain—Doxorubicin—thyroid cancer	0.000809	0.000951	CcSEcCtD
Dorzolamide—Body temperature increased—Doxorubicin—thyroid cancer	0.000809	0.000951	CcSEcCtD
Dorzolamide—Asthenia—Epirubicin—thyroid cancer	0.000793	0.000933	CcSEcCtD
Dorzolamide—Pruritus—Epirubicin—thyroid cancer	0.000782	0.00092	CcSEcCtD
Dorzolamide—Diarrhoea—Epirubicin—thyroid cancer	0.000757	0.00089	CcSEcCtD
Dorzolamide—Hypersensitivity—Doxorubicin—thyroid cancer	0.000754	0.000886	CcSEcCtD
Dorzolamide—Asthenia—Doxorubicin—thyroid cancer	0.000734	0.000863	CcSEcCtD
Dorzolamide—Dizziness—Epirubicin—thyroid cancer	0.000731	0.00086	CcSEcCtD
Dorzolamide—Pruritus—Doxorubicin—thyroid cancer	0.000724	0.000851	CcSEcCtD
Dorzolamide—Vomiting—Epirubicin—thyroid cancer	0.000703	0.000827	CcSEcCtD
Dorzolamide—Diarrhoea—Doxorubicin—thyroid cancer	0.0007	0.000823	CcSEcCtD
Dorzolamide—Rash—Epirubicin—thyroid cancer	0.000697	0.00082	CcSEcCtD
Dorzolamide—Dermatitis—Epirubicin—thyroid cancer	0.000697	0.000819	CcSEcCtD
Dorzolamide—Headache—Epirubicin—thyroid cancer	0.000693	0.000815	CcSEcCtD
Dorzolamide—Dizziness—Doxorubicin—thyroid cancer	0.000677	0.000796	CcSEcCtD
Dorzolamide—CYP2C9—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000666	0.0168	CbGpPWpGaD
Dorzolamide—Nausea—Epirubicin—thyroid cancer	0.000657	0.000772	CcSEcCtD
Dorzolamide—Vomiting—Doxorubicin—thyroid cancer	0.000651	0.000765	CcSEcCtD
Dorzolamide—Rash—Doxorubicin—thyroid cancer	0.000645	0.000759	CcSEcCtD
Dorzolamide—Dermatitis—Doxorubicin—thyroid cancer	0.000645	0.000758	CcSEcCtD
Dorzolamide—Headache—Doxorubicin—thyroid cancer	0.000641	0.000754	CcSEcCtD
Dorzolamide—Nausea—Doxorubicin—thyroid cancer	0.000608	0.000715	CcSEcCtD
Dorzolamide—CA9—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.000586	0.0147	CbGpPWpGaD
Dorzolamide—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.000575	0.0145	CbGpPWpGaD
Dorzolamide—CA9—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.00056	0.0141	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—MINPP1—thyroid cancer	0.000474	0.0119	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—MINPP1—thyroid cancer	0.000462	0.0116	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—MINPP1—thyroid cancer	0.000462	0.0116	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—MINPP1—thyroid cancer	0.000432	0.0109	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—MINPP1—thyroid cancer	0.000432	0.0109	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—NDUFA13—thyroid cancer	0.000403	0.0102	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—MINPP1—thyroid cancer	0.0004	0.0101	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—NDUFA13—thyroid cancer	0.000393	0.00989	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—NDUFA13—thyroid cancer	0.000393	0.00989	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—CHST14—thyroid cancer	0.000379	0.00954	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—CHST14—thyroid cancer	0.00037	0.0093	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—CHST14—thyroid cancer	0.00037	0.0093	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—NDUFA13—thyroid cancer	0.000367	0.00923	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—NDUFA13—thyroid cancer	0.000367	0.00923	CbGpPWpGaD
Dorzolamide—CA1—C-MYB transcription factor network—PTGS2—thyroid cancer	0.000352	0.00885	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—CHST14—thyroid cancer	0.000345	0.00868	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—CHST14—thyroid cancer	0.000345	0.00868	CbGpPWpGaD
Dorzolamide—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000344	0.00866	CbGpPWpGaD
Dorzolamide—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000344	0.00865	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—NDUFA13—thyroid cancer	0.00034	0.00856	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—CHST14—thyroid cancer	0.00032	0.00804	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—MINPP1—thyroid cancer	0.000319	0.00802	CbGpPWpGaD
Dorzolamide—CA1—C-MYB transcription factor network—CCND1—thyroid cancer	0.000318	0.00799	CbGpPWpGaD
Dorzolamide—CA9—Cellular responses to stress—EPO—thyroid cancer	0.000311	0.00782	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—MINPP1—thyroid cancer	0.000306	0.00769	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—HPGD—thyroid cancer	0.000306	0.00769	CbGpPWpGaD
Dorzolamide—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	0.000303	0.00763	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—HPGD—thyroid cancer	0.000298	0.0075	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—HPGD—thyroid cancer	0.000298	0.0075	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—MINPP1—thyroid cancer	0.000293	0.00737	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—HPGD—thyroid cancer	0.000278	0.007	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—HPGD—thyroid cancer	0.000278	0.007	CbGpPWpGaD
Dorzolamide—CA1—C-MYB transcription factor network—NRAS—thyroid cancer	0.000274	0.00688	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—NDUFA13—thyroid cancer	0.000271	0.00682	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—NDUFA13—thyroid cancer	0.00026	0.00654	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—MINPP1—thyroid cancer	0.000258	0.00648	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—HPGD—thyroid cancer	0.000258	0.00648	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—CHST14—thyroid cancer	0.000255	0.00641	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—NDUFA13—thyroid cancer	0.000249	0.00627	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—CHST14—thyroid cancer	0.000244	0.00615	CbGpPWpGaD
Dorzolamide—CA1—C-MYB transcription factor network—KRAS—thyroid cancer	0.000235	0.00592	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—CHST14—thyroid cancer	0.000234	0.0059	CbGpPWpGaD
Dorzolamide—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000227	0.0057	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—NDUFA13—thyroid cancer	0.000219	0.00551	CbGpPWpGaD
Dorzolamide—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000208	0.00523	CbGpPWpGaD
Dorzolamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000207	0.0052	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—CHST14—thyroid cancer	0.000206	0.00518	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—HPGD—thyroid cancer	0.000205	0.00517	CbGpPWpGaD
Dorzolamide—CA1—C-MYB transcription factor network—HRAS—thyroid cancer	0.0002	0.00504	CbGpPWpGaD
Dorzolamide—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.0002	0.00503	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—HPGD—thyroid cancer	0.000197	0.00496	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—HPGD—thyroid cancer	0.000189	0.00475	CbGpPWpGaD
Dorzolamide—CA9—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	0.000188	0.00474	CbGpPWpGaD
Dorzolamide—CA9—Cellular responses to stress—HIF1A—thyroid cancer	0.000185	0.00465	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—TPR—thyroid cancer	0.000176	0.00442	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—PRKAR1A—thyroid cancer	0.000173	0.00435	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—TPR—thyroid cancer	0.000171	0.00431	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—TPR—thyroid cancer	0.000171	0.00431	CbGpPWpGaD
Dorzolamide—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000169	0.00424	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—PRKAR1A—thyroid cancer	0.000168	0.00424	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—PRKAR1A—thyroid cancer	0.000168	0.00424	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—HPGD—thyroid cancer	0.000166	0.00418	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—TPR—thyroid cancer	0.00016	0.00402	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—TPR—thyroid cancer	0.00016	0.00402	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—PRKAR1A—thyroid cancer	0.000157	0.00395	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—PRKAR1A—thyroid cancer	0.000157	0.00395	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—TPR—thyroid cancer	0.000148	0.00372	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—PRKAR1A—thyroid cancer	0.000146	0.00366	CbGpPWpGaD
Dorzolamide—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000137	0.00345	CbGpPWpGaD
Dorzolamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000136	0.00343	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—SLC5A5—thyroid cancer	0.000131	0.00331	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—SLC5A5—thyroid cancer	0.000128	0.00322	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—SLC5A5—thyroid cancer	0.000128	0.00322	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—SLC5A5—thyroid cancer	0.00012	0.00301	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—SLC5A5—thyroid cancer	0.00012	0.00301	CbGpPWpGaD
Dorzolamide—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000119	0.00301	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—TPR—thyroid cancer	0.000118	0.00297	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—PRKAR1A—thyroid cancer	0.000116	0.00292	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—TPR—thyroid cancer	0.000113	0.00285	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—PRKAR1A—thyroid cancer	0.000111	0.0028	CbGpPWpGaD
Dorzolamide—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000111	0.0028	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—SLC5A5—thyroid cancer	0.000111	0.00279	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—RXRA—thyroid cancer	0.00011	0.00278	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—TPR—thyroid cancer	0.000108	0.00273	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—RXRA—thyroid cancer	0.000108	0.00271	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—RXRA—thyroid cancer	0.000108	0.00271	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—PRKAR1A—thyroid cancer	0.000107	0.00269	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—RXRA—thyroid cancer	0.0001	0.00253	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—RXRA—thyroid cancer	0.0001	0.00253	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—TPR—thyroid cancer	9.54e-05	0.0024	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	9.52e-05	0.00239	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—PRKAR1A—thyroid cancer	9.38e-05	0.00236	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—RXRA—thyroid cancer	9.31e-05	0.00234	CbGpPWpGaD
Dorzolamide—CYP2C9—Biological oxidations—RXRA—thyroid cancer	8.95e-05	0.00225	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—SLC5A5—thyroid cancer	8.83e-05	0.00222	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—SLC5A5—thyroid cancer	8.47e-05	0.00213	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—SLC5A5—thyroid cancer	8.12e-05	0.00204	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—RXRA—thyroid cancer	7.42e-05	0.00187	CbGpPWpGaD
Dorzolamide—CA9—Cellular responses to stress—TP53—thyroid cancer	7.36e-05	0.00185	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—SLC5A5—thyroid cancer	7.14e-05	0.0018	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—RXRA—thyroid cancer	7.12e-05	0.00179	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—PPARG—thyroid cancer	6.97e-05	0.00175	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—RXRA—thyroid cancer	6.82e-05	0.00172	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—PPARG—thyroid cancer	6.8e-05	0.00171	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—PPARG—thyroid cancer	6.8e-05	0.00171	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—MINPP1—thyroid cancer	6.58e-05	0.00165	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—PPARG—thyroid cancer	6.34e-05	0.0016	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—PPARG—thyroid cancer	6.34e-05	0.0016	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—RXRA—thyroid cancer	6e-05	0.00151	CbGpPWpGaD
Dorzolamide—CYP3A4—Biological oxidations—RXRA—thyroid cancer	5.9e-05	0.00149	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—PPARG—thyroid cancer	5.88e-05	0.00148	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—NDUFA13—thyroid cancer	5.59e-05	0.00141	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—PTGS2—thyroid cancer	5.49e-05	0.00138	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—PTGS2—thyroid cancer	5.35e-05	0.00135	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—PTGS2—thyroid cancer	5.35e-05	0.00135	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—CHST14—thyroid cancer	5.26e-05	0.00132	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—PTGS2—thyroid cancer	4.99e-05	0.00126	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—PTGS2—thyroid cancer	4.99e-05	0.00126	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—PTEN—thyroid cancer	4.78e-05	0.0012	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—PPARG—thyroid cancer	4.69e-05	0.00118	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—PTEN—thyroid cancer	4.66e-05	0.00117	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—PTEN—thyroid cancer	4.66e-05	0.00117	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—PTGS2—thyroid cancer	4.62e-05	0.00116	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—PPARG—thyroid cancer	4.49e-05	0.00113	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—PTEN—thyroid cancer	4.35e-05	0.0011	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—PTEN—thyroid cancer	4.35e-05	0.0011	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—MINPP1—thyroid cancer	4.34e-05	0.00109	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—PPARG—thyroid cancer	4.31e-05	0.00108	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—HPGD—thyroid cancer	4.24e-05	0.00107	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—PTEN—thyroid cancer	4.03e-05	0.00101	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—PPARG—thyroid cancer	3.79e-05	0.000953	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—NDUFA13—thyroid cancer	3.69e-05	0.000928	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—PTGS2—thyroid cancer	3.69e-05	0.000928	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—PTGS2—thyroid cancer	3.53e-05	0.000889	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—CHST14—thyroid cancer	3.47e-05	0.000873	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.44e-05	0.000865	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—PTGS2—thyroid cancer	3.39e-05	0.000853	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—PTEN—thyroid cancer	3.22e-05	0.000809	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—PTEN—thyroid cancer	3.08e-05	0.000776	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—PTGS2—thyroid cancer	2.98e-05	0.00075	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—PTEN—thyroid cancer	2.96e-05	0.000744	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—HPGD—thyroid cancer	2.8e-05	0.000703	CbGpPWpGaD
Dorzolamide—CA14—Metabolism—AKT1—thyroid cancer	2.76e-05	0.000694	CbGpPWpGaD
Dorzolamide—CA6—Metabolism—AKT1—thyroid cancer	2.69e-05	0.000676	CbGpPWpGaD
Dorzolamide—CA5A—Metabolism—AKT1—thyroid cancer	2.69e-05	0.000676	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—PTEN—thyroid cancer	2.6e-05	0.000654	CbGpPWpGaD
Dorzolamide—CA7—Metabolism—AKT1—thyroid cancer	2.51e-05	0.000631	CbGpPWpGaD
Dorzolamide—CA5B—Metabolism—AKT1—thyroid cancer	2.51e-05	0.000631	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—TPR—thyroid cancer	2.43e-05	0.000613	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	2.39e-05	0.000603	CbGpPWpGaD
Dorzolamide—CA12—Metabolism—AKT1—thyroid cancer	2.32e-05	0.000585	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.17e-05	0.000546	CbGpPWpGaD
Dorzolamide—CA4—Metabolism—AKT1—thyroid cancer	1.85e-05	0.000466	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—SLC5A5—thyroid cancer	1.82e-05	0.000459	CbGpPWpGaD
Dorzolamide—CA2—Metabolism—AKT1—thyroid cancer	1.78e-05	0.000447	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.71e-05	0.00043	CbGpPWpGaD
Dorzolamide—CA1—Metabolism—AKT1—thyroid cancer	1.7e-05	0.000429	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—TPR—thyroid cancer	1.61e-05	0.000404	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.58e-05	0.000397	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—RXRA—thyroid cancer	1.53e-05	0.000385	CbGpPWpGaD
Dorzolamide—CA9—Metabolism—AKT1—thyroid cancer	1.5e-05	0.000377	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.49e-05	0.000375	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.2e-05	0.000302	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—RXRA—thyroid cancer	1.01e-05	0.000254	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—PPARG—thyroid cancer	9.67e-06	0.000243	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—PTGS2—thyroid cancer	7.6e-06	0.000191	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—PTEN—thyroid cancer	6.63e-06	0.000167	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—PPARG—thyroid cancer	6.38e-06	0.00016	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—PTGS2—thyroid cancer	5.02e-06	0.000126	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—PTEN—thyroid cancer	4.37e-06	0.00011	CbGpPWpGaD
Dorzolamide—CYP2C9—Metabolism—AKT1—thyroid cancer	3.82e-06	9.62e-05	CbGpPWpGaD
Dorzolamide—CYP3A4—Metabolism—AKT1—thyroid cancer	2.52e-06	6.34e-05	CbGpPWpGaD
